Key result
Serial Rubidium-82 PET-CT shows apical microvascular response to mavacamten in obstructive HCM.
Why the study?
Microvascular dysfunction is a recognized complication of hypertrophic cardiomyopathy and independently predicts adverse outcomes, but its response to mavacamten is not well characterized.
Does mavacamten improve apical microvascular response as assessed by serial Rubidium-82 PET-CT in obstructive hypertrophic cardiomyopathy?
Case Report
Does mavacamten improve apical microvascular response as assessed by serial Rubidium-82 PET-CT in obstructive hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
This case report explores the utility of serial Rubidium-82 PET-CT to quantify the apical microvascular response to mavacamten therapy in obstructive hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) affects approximately 1 in 500 individuals.1 Microvascular dysfunction (MVD), driven by myocardial hypertrophy, small intramural coronary artery dysplasia, fibrosis, and elevated filling pressures, is a recognised complication of HCM and independently predicts adverse outcomes.2 Rb-82 PET-CT with absolute myocardial blood flow (MBF) quantification is the reference standard for non-invasive MVD assessment.3
No takes yet. Share an insight, caveat, or question.
Naneishvili et al. (2026) conducted a case report in Obstructive Hypertrophic Cardiomyopathy. Mavacamten was evaluated. This case report presents the apical microvascular response to mavacamten in obstructive hypertrophic cardiomyopathy as assessed by serial Rubidium-82 PET-CT.
Synapse has enriched 10 related papers. Consider them for comparative context: